October 2026 brought several US Food and Drug Administration (FDA) regulatory actions with potential implications for primary care, spanning psychiatric treatment, cancer detection, stroke rehabilitation, and cardiovascular disease management. Among the developments, the FDA approved olanzapine extended-release injectable suspension (Weltruza), a once-monthly treatment for adults with schizophrenia that does not require oral supplementation or postinjection monitoring. Abbott also received FDA approval for updates to its CardioMEMS HF System, allowing patients with heart failure to view pulmonary artery pressure readings and receive individualized treatment instructions through a smartphone app.

Other October actions focused on investigational technologies addressing unmet clinical needs. Natera received Breakthrough Device designation for its multi-cancer early detection blood test, which uses cell-free DNA analysis to screen for multiple cancers, while NeuWire Medical secured Investigational Device Exemption approval to initiate a pivotal trial evaluating neurostimulation-assisted rehabilitation for patients with chronic ischemic stroke. Although neither action constitutes FDA marketing authorization, both represent steps toward evaluating technologies that could eventually expand diagnostic and treatment options. Below are 4 FDA updates from October that primary care physicians should know.

1. FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia

On October 9, 2026, Teva Pharmaceuticals announced FDA approval of olanzapine extended-release injectable suspension (Weltruza), a once-monthly subcutaneous treatment for adults with schizophrenia. Based on results from the phase 3 SOLARIS trial involving 675 adults, all 3 doses significantly improved Positive and Negative Syndrome Scale total scores compared with placebo at week 8 (adjusted P<.001 for each comparison). The formulation requires no loading dose, oral supplementation, or postinjection monitoring, potentially reducing treatment burden for patients receiving antipsychotic therapy. No cases of postinjection delirium/sedation syndrome were observed across 3470 injections, although weight gain and metabolic adverse effects remain important safety considerations.

2. FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test

On October 9, 2026, Natera announced FDA Breakthrough Device designation for its investigational multi-cancer early detection (MCED) blood test designed to screen for multiple cancers using cell-free DNA analysis. Based on data spanning 12 cancer types, the FDA evaluated the assay’s sensitivity, specificity, and ability to predict the anatomical origin of a detected cancer signal. Natera did not disclose specific performance results or identify the cancer types included in the evaluation. The designation is intended to expedite development and regulatory review, but the assay remains investigational and has not received FDA clearance or approval.

3. FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke

On October 5, 2026, NeuWire Medical announced FDA Investigational Device Exemption (IDE) approval to initiate the pivotal STROKE-REWIRE trial evaluating its investigational ReWire Vagus Nerve Stimulation System for upper-limb dysfunction following chronic ischemic stroke. Based on the approved study design, the randomized, sham-controlled trial will enroll up to 135 participants across 12 US clinical sites to evaluate the safety and efficacy of vagus nerve stimulation paired with rehabilitation. The device is designed to deliver stimulation during successful rehabilitation movements to promote neuroplasticity and improve arm and hand function. IDE approval authorizes clinical investigation but does not establish device safety or efficacy or constitute FDA marketing approval.

4. Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones

On October 5, 2026, Abbott announced FDA approval of updates to its CardioMEMS HF System that allow patients with heart failure to view pulmonary artery pressure readings and receive personalized treatment instructions through the CardioGuide HF smartphone app. Based on the system’s existing remote monitoring capabilities, the new features enable patients with implanted CardioMEMS sensors to track pressure trends that may signal worsening heart failure before symptoms develop. The Dynamic Treatment Plan feature also allows clinicians to send individualized medication adjustment instructions directly to patients based on changes in pulmonary artery pressure. Abbott expects the new features to become available later this year, although their impact on hospitalizations, medication adherence, and patient engagement has not yet been established.